Astellas Pharma Inc (ALPMF) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much for your attendance on this Q3 Y2D FY24 Financial Results Announcement Meeting. I'm going to serve as a moderator. I'm Chief Communications and IR Officer, Ikeda. We make a presentation first, and after that, we'll have a Q&A session. The presentation is given based upon the presentation material posted on our website, including a Q&A. The simultaneous translation for both Japanese and English are provided. For simultaneous translation, the accuracy cannot be guaranteed by the company. You can select the language from Zoom webinar screen menu. If you select the original language, then you can hear the original sounds without the interpreter's voices. This is some disclaimer. This material or presentation by representatives for the company and answers and statement by representatives for the company in the QA session includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management as subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors. They contain information of pharmaceuticals including compounds under development. This information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations. Now, let me introduce you, the participants here, the Asushi Kitamura CFO, Chief Financial Officer. Can't you tell the yours to go shitaka chief scientific officer? Medical Tanto Tadaki Taniguchi, chief medical officer. How might talk about class silver chief commercial officer? We have these four representatives here now. Akitamura simply start the presentation. Hello, everyone. I'm Atsushi Kitamura from Astellas Pharma Inc. Thank you very much for joining...